Should You Buy Ocugen Stock in March?

Shares in Ocugen (NASDAQ: OCGN), a Malvern, Penn., biopharmaceutical company, were below $0.30 a share as recently as Dec. 15, and now, they're just above $8 a share. That's after climbing to $10 a share earlier this week. Over the past three months, the company's shares have risen more than 2,500%.

What's behind all of this investor enthusiasm? It isn't the company's balance sheet, at least not yet. Ocugen is a clinical-stage company whose early-stage gene therapies are aimed at preventing or suppressing inherited eye diseases that cause blindness.

Its pipeline includes just three therapies, led by OCU400, which has four U.S. Food and Drug Administration (FDA) orphan drug designations with the potential to treat more than 150 gene mutations of retinitis pigmentosa, a disease that causes a loss of cells in the retina and can lead to blindness.

Source Fool.com